FDMT - 4D Molecular Therapeutics gets FDA RMAT status for macular edema treatment
2025-05-01 10:11:30 ET
More on 4D Molecular Therapeutics
- 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
- Cantor analysts call for RFK Jr. replacement following ousting of Marks at FDA
- How Peter Marks' FDA departure is impacting pharma, biotech stocks
- Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics
- Historical earnings data for 4D Molecular Therapeutics